16 Minutes News by a16z

J&J Vaccine Pause; FBI Accesses Servers in Exchange Hack

16 Minutes News by a16z

Show Notes

We have two brief segments in today’s episode: News and analysis of the Johnson & Johnson COVID vaccine pause, and the widespread hack of Microsoft Exchange Servers across the country (and the dramatic and unusual steps the FBI took in response).

Johnson & Johnson: Federal health officials last week revealed that six women who received the vaccine had developed rare and severe blood clots in their brain, in one case fatally. Even more recently, a panel of expert advisors to the Centers for Disease Control determined that they needed more time to assess the risk of the drug, which was approved by the FDA under Emergency Use Authorization, or EUA.

Our experts are General Partner Jorge Conde, who previously appeared on a episode on J&J efficacy rates, and General Partner Vineeta Agarwala, who is also a practicing clinician at Stanford Hospital, and recently joined us on "16 Minutes" with Dr. Bob Wachter of UCSF to analyze the vaccine rollout in the U.S. They address the clinical facts about the six J&J cases (and contrast it to the social media conversations and headlines), the incidence rate, and what the J&J vaccine shares with the Astra Zeneca vaccine, which has been halted or limited in Europe and elsewhere over similar blood clot concerns.

FBI and Microsoft Exchange Servers: The Department of Justice recently announced that the FBI, after getting court authorization, had removed malicious code from hundreds of computers running on-premises versions of Microsoft Exchange Server software used to provide email services. In March, Microsoft had announced the initial hack and released detection tools and patches to help owners of the compromised computers, but the latest government announcement revealed that the FBI had taken the step of removing the malicious code, in this case web shells that enable remote administration, from computers that had not mitigated the risk. Microsoft has associated the hackers with state-sponsored actors in China.

Our expert is a16z's Joel de la Garza, who explains what’s behind this unusual action and figure out where it fits into larger trends of enterprise security and even national security.

###

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of invest

More from 16 Minutes News by a16z

Feb 22, 2022

with @rvenkayya @jorgecondebio @smc90

Dec 20, 2021

Welcome to 16 Minutes, our podcast where we discuss tech trends in the news and their impact on the long arc of innovation. Today’s topic is crypto regulation, and specifically, two recent federal government hearings in the news that were focused on crypto and therefore the related trend of web3. In contrast to the model of web2 — typified by very broadly used but also very centralized platforms run by corporations — web3 refers to the idea of a new internet enabled by crypto that is owned by builders and users.

Dec 3, 2021

Welcome to 16 Minutes, our show on the a16z podcast network where we talk about tech trends that are dominating news headlines, industry buzz, and where we are on the long arc of innovation.

Oct 26, 2021

Welcome to 16 Minutes, our show where we talk about tech trends in the news. We have two segments today: 1) The announcement recently that Valve Software, which operates the massive gaming platform Steam, added a rule against games that use blockchain technologies or that allow users to exchange cryptocurrencies or NFTs – this rule appeared on its “What you shouldn’t publish on Steam” onboarding list for developers. We go beyond the players to the trends at play here, putting the news in context — as is the premise of this show — because it not only immediately impacts gaming developers and gamers using the platform, but has implications for gaming business models and the arc of innovation in gaming as part of the web3 movement. Our expert guests are a16z partner Jonathan Lai and a16z partner Eddy Lazzarin. 2) The FDA’s announcement last month that it authorized marketing of the “first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.” The FDA reviewed the technology from Paige Prostate through its De Novo regulatory pathway. We have three expert guests: Eli Van Allen, associate professor of Medicine at Harvard Medical School and chief of the Division of Population Sciences at the Dana-Farber Cancer Institute; a16z bio general partner Vineeta Agarwala; and a16z bio partner Jay Rughani.

Aug 2, 2021

In today’s episode we have two short segments, both on bioscience topics:

See all episodes →